Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:53:07 EST Wed 17 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ANAB - ANAPTYSBIO INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ANAB - Q0.143.50·47.009.045.03-0.53-1.2318.214,0044,42845.10  46.00  44.02847.856  12.2117:59:17Dec 1515 min RT 2¢

Recent Trades - Last 10 of 4428
Time ETExPriceChangeVolume
17:59:17Q45.720.161
17:34:06Q45.03-0.532
17:01:33Q46.410.8550
16:41:34Q44.59-0.971
16:31:46Q45.50-0.06100
16:20:00Q45.03-0.5361
16:11:21Q45.03-0.5311
16:10:04Q45.03-0.531
16:10:04Q45.03-0.531
16:04:39Q45.03-0.531

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-15 07:00U:ANABNews ReleaseVanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
2025-11-25 16:15U:ANABNews ReleaseAnaptys Announces Participation in December Investor Conferences
2025-11-21 04:00U:ANABNews ReleaseAnaptys Announces $100 Million Stock Repurchase Plan
2025-11-21 03:50U:ANABNews ReleaseAnaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
2025-11-10 09:00U:ANABNews ReleaseAnaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
2025-11-04 16:15U:ANABNews ReleaseAnaptys Announces Participation in November Investor Conferences
2025-11-04 16:15U:ANABNews ReleaseAnaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
2025-10-29 09:15U:ANABNews ReleaseAnaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
2025-10-13 09:15U:ANABNews ReleaseAnaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
2025-09-29 16:06U:ANABNews ReleaseAnaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
2025-09-29 16:06U:ANABNews ReleaseAnaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
2025-08-27 16:15U:ANABNews ReleaseAnaptys Announces Participation in September Investor Conferences
2025-08-06 16:16U:ANABNews ReleaseAnaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
2025-06-03 16:05U:ANABNews ReleaseAnaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
2025-05-27 16:15U:ANABNews ReleaseAnaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
2025-05-05 16:15U:ANABNews ReleaseAnaptys Announces First Quarter 2025 Financial Results and Provides Business Update
2025-03-24 09:15U:ANABNews ReleaseAnaptys Announces Stock Repurchase Plan
2025-02-27 16:15U:ANABNews ReleaseAnaptys Announces Participation in March Investor Conferences
2025-02-27 16:15U:ANABNews ReleaseAnaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-12 07:30U:ANABNews ReleaseAnaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months